Tirzepatide Microdose
Low-Dose Dual GLP-1/GIP Microdosing Program
A smarter, gentler approach to dual-action weight loss. Tirzepatide Microdose uses a low, starter-level dose that activates both GLP-1 and GIP receptors — designed for people who want gradual appetite and craving control with the added benefit of dual-receptor therapy, especially first-time users or anyone sensitive to side effects.
From $165/mo
Monthly (Cancel Anytime) | 3-Month & 6-Month Bundles Available
Approach
Start Low, Go Slow
Rx Required
Yes — Prescribed Online
Pharmacy
US-Registered
Shipping
Free & Discreet
Dual-Action Weight Loss, Gentle Start
Tirzepatide Microdose combines the power of two receptor pathways — GLP-1 and GIP — at a low, introductory dose. While standard tirzepatide targets both pathways at higher clinical doses, the microdose approach lets your body adjust more gradually, significantly reducing the likelihood of common side effects like nausea, fatigue, and digestive discomfort.
This dual-action mechanism is what sets tirzepatide apart from semaglutide. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation enhances insulin sensitivity, improves fat metabolism, and may provide additional appetite-suppressing effects. Together, these two pathways can deliver more comprehensive metabolic support — even at lower doses.
Tirzepatide Microdose is ideal for first-time GLP-1 users, patients who have experienced side effects on higher doses, or anyone who prefers to ease into treatment. Your physician will carefully titrate your dose over time based on how your body responds, following a "start low, go slow" approach that prioritizes comfort without sacrificing results.
Why Choose Tirzepatide Microdose
Start Low, Go Slow
Begin with lower doses that let your body adjust naturally, minimizing discomfort while your system adapts to the dual-action medication.
Fewer Side Effects
Most patients on microdose protocols experience significantly reduced nausea, fatigue, and digestive issues compared to standard starting doses of tirzepatide.
Sustainable Results
Build healthy habits over time for lasting weight management success. A gradual approach helps establish a long-term relationship with the medication.
Dual GLP-1/GIP Action
Tirzepatide targets both GLP-1 and GIP receptors simultaneously — providing broader metabolic support for appetite, blood sugar, and fat metabolism than single-receptor medications.
Physician-Guided Titration
Your licensed provider carefully monitors your response and adjusts dosing over time to find your optimal level for maximum results with minimal discomfort.
100% Online
No office visits. Complete your evaluation online, get prescribed by a licensed physician, and have your medication shipped free to your door.
What to Expect
Getting Started
You'll begin with a low microdose of Tirzepatide that activates both GLP-1 and GIP pathways gently. This dual-receptor introduction allows your body to acclimate gradually. Most patients notice a subtle reduction in appetite and improved satiety within the first couple of weeks.
Gradual Adjustment
Your physician monitors your response, comfort level, and metabolic markers. If appropriate, dosing is slowly increased to optimize appetite suppression and metabolic benefits while keeping side effects minimal. Every patient's titration schedule is personalized.
Sustained Progress
As your body adjusts, the dual GLP-1/GIP action provides consistent appetite control, improved insulin sensitivity, and steady weight loss. The microdose approach helps you build sustainable habits that support long-term success without the shock of high initial doses.
Important Safety Information
Compounded tirzepatide is not FDA-approved. It is prepared by a US-registered compounding pharmacy under a physician's prescription. Side effects may include nausea, vomiting, diarrhea, constipation, and stomach pain — the microdose approach is designed to minimize these effects through gradual titration.
Tirzepatide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy or breastfeeding. Tirzepatide may also affect blood sugar levels — patients with diabetes should consult their healthcare provider before starting treatment. Always consult your healthcare provider to determine if this treatment is appropriate for you.
Ready for dual-action weight loss?
Complete a brief online evaluation to see if Tirzepatide Microdose is right for you. A licensed provider will review your health profile and create a personalized dual-action microdosing plan.